Stock ECX EPIGENOMICS AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Epigenomics AG Xetra

Equities

ECX

DE000A11QW50

End-of-day quote Xetra
Other stock markets
 04:30:00 05/02/2024 am IST 		5-day change 1st Jan Change
1.89 EUR -.--% Intraday chart for Epigenomics AG +8.31% -.--%
14/03 Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EPIGENOMICS AG Stock Epigenomics AG
-.--% 1.53M -
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-18.16% 11.13B
A-
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+58.43% 3.6B
D+
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-31.31% 2.26B
C
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.31% 2.16B -
B-
VERACYTE, INC. Stock Veracyte, Inc.
-26.61% 1.54B
C+
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+34.35% 1.17B
B-
SEEGENE, INC. Stock Seegene, Inc.
-3.28% 744M
C+
CAREDX, INC Stock CareDx, Inc
-22.75% 482M
C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-40.20% 432M
C-
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. ECX Stock
  4. ECX Stock
  5. Ratings Epigenomics AG